NorgesInvestor
NorgesInvestor, established in 1996, is a Norwegian asset management firm headquartered in Oslo with an additional office in Stockholm. The company specializes in strategic and financial value creation through various investment activities. These include private equity funds, where they actively manage investments in mature and growth companies across sectors such as telecommunications, information technology, retail, and manufacturing in Norway and Sweden. They also offer discretionary wealth management services and invest in listed securities. NorgesInvestor is privately-owned, financially robust, and independent.
Top Stages
1 past transactions
Algeta
Series A in 2005
Algeta ASA is an oncology company headquartered in Oslo, Norway, that specializes in developing targeted therapies for cancer treatment using its proprietary alpha-pharmaceutical platform. Founded in 1997, the company focuses on fulfilling unmet medical needs in cancer care. Its lead product, radium-223 dichloride, has successfully completed Phase III clinical trials for treating castration-resistant prostate cancer with bone metastases. Additionally, Algeta is advancing its research on thorium-227, an alpha-emitter that is in the preclinical phase and is being developed in conjunction with tumor-targeting molecules to create targeted thorium conjugates. The company has a collaboration agreement with Bayer Pharma AG for the global development and commercialization of radium-223. Algeta was previously known as Anticancer Therapeutic Inventions AS before rebranding in 2003.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.